GNLX
insider transactionsGENELUX Corp — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-30.4K
0 buy · 30.4K sell
Net value · 365d
-$86.4K
$0 in · $86.4K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
12
0 buy · 30.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Matthew Pulisic KEY
Chief Financial Officer
$0
278.9K sh
Own New
-
Grant·A
General Counsel
$0
234.0K sh
Own New
-
Grant·A
Director
$0
31.6K sh
Own New
-
Grant·A
Director
$0
28.4K sh
Own +42%
-
Grant·A
Thomas Zindrick KEY
President and CEO
$0
730.6K sh
Own +137%
-
Grant·A
Director
$0
31.6K sh
Own New
-
Grant·A
Director
$0
28.4K sh
Own +6%
-
Grant·A
Director
$0
31.6K sh
Own New
-
Grant·A
Director
$0
28.4K sh
Own +38%
-
Grant·A
Chief Scientific Officer
$0
119.3K sh
Own +80%
-
Grant·A
Director
$0
31.6K sh
Own New
-
Grant·A
Director
$0
28.4K sh
Own +38%
-
Grant·A
Chief Technical Officer
$0
174.8K sh
Own +113%
-
Sell·S
Head of Regulatory
$563
192 sh · $2.93
Own -0%
-
Sell·S
Director · 10b5-1
$29.8K
10.0K sh · $2.98
Own -2%
-
Sell·S
Chief Scientific Officer
$1.8K
605 sh · $2.97
Own -0%
-
Sell·S
Thomas Zindrick KEY
President and CEO
$8.2K
2.8K sh · $2.94
Own -1%
-
Sell·S
Head of Regulatory
$804
270 sh · $2.98
Own -0%
-
Sell·S
Chief Technical Officer
$1.8K
605 sh · $2.97
Own -0%
-
Sell·S
Head of Regulatory
$602
240 sh · $2.51
Own -0%
-
Sell·S
Head of Regulatory
$835
345 sh · $2.42
Own -1%
-
Sell·S
SVP, Clinical Development
$2.2K
906 sh · $2.42
Own -1%
-
Sell·S
Thomas Zindrick KEY
President and CEO
$8.7K
3.6K sh · $2.42
Own -1%
-
Sell·S
Chief Technical Officer
$2.2K
906 sh · $2.42
Own -1%
-
Sell·S
Director · 10b5-1
$29.0K
10.0K sh · $2.90
Own -2%
-
Grant·A
Chief Medical Officer
$0
275.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 16, 2026 | Matthew Pulisic KEY | Grant A | 278.9K | $0 |
| Jun 16, 2026 | Eric Groen | Grant A | 234.0K | $0 |
| Jun 16, 2026 | James L Tyree | Grant A | 31.6K | $0 |
| Jun 16, 2026 | James L Tyree | Grant A | 28.4K | $0 |
| Jun 16, 2026 | Thomas Zindrick KEY | Grant A | 730.6K | $0 |
| Jun 16, 2026 | John Thomas | Grant A | 31.6K | $0 |
| Jun 16, 2026 | John Thomas | Grant A | 28.4K | $0 |
| Jun 16, 2026 | Mary Mirabelli | Grant A | 31.6K | $0 |
| Jun 16, 2026 | Mary Mirabelli | Grant A | 28.4K | $0 |
| Jun 16, 2026 | Yong Yu | Grant A | 119.3K | $0 |
| Jun 16, 2026 | John W Smither | Grant A | 31.6K | $0 |
| Jun 16, 2026 | John W Smither | Grant A | 28.4K | $0 |
| Jun 16, 2026 | Joseph Cappello | Grant A | 174.8K | $0 |
| Jun 3, 2026 | Ralph Smalling | Sell S | 192 | $563 |
| Jun 1, 2026 | John Thomas 10b5-1 | Sell S | 10.0K | $29.8K |
| May 11, 2026 | Yong Yu | Sell S | 605 | $1.8K |
| May 11, 2026 | Thomas Zindrick KEY | Sell S | 2.8K | $8.2K |
| May 11, 2026 | Ralph Smalling | Sell S | 270 | $804 |
| May 11, 2026 | Joseph Cappello | Sell S | 605 | $1.8K |
| Mar 25, 2026 | Ralph Smalling | Sell S | 240 | $602 |
| Mar 24, 2026 | Ralph Smalling | Sell S | 345 | $835 |
| Mar 24, 2026 | Yong Yu | Sell S | 906 | $2.2K |
| Mar 24, 2026 | Thomas Zindrick KEY | Sell S | 3.6K | $8.7K |
| Mar 24, 2026 | Joseph Cappello | Sell S | 906 | $2.2K |
| Mar 2, 2026 | John Thomas 10b5-1 | Sell S | 10.0K | $29.0K |
| Jan 2, 2026 | Jason Litten | Grant A | 275.0K | $0 |
About GNLX insider trading
This page tracks insider transactions for GENELUX Corp (GNLX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.